Mechanisms of chemotherapy-induced peripheral neuropathy
R Zajączkowska, M Kocot-Kępska, W Leppert… - International journal of …, 2019 - mdpi.com
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side
effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically …
effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically …
Chemotherapy‐induced peripheral neuropathy: a current review
Chemotherapy‐induced peripheral neuropathy (CIPN) is a common dose‐limiting side effect
experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients …
experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients …
Pathophysiology of chemotherapy-induced peripheral neuropathy
Chemotherapy-induced neuropathy is a common, dose-dependent adverse effect of several
antineoplastics. It can lead to detrimental dose reductions and discontinuation of treatment …
antineoplastics. It can lead to detrimental dose reductions and discontinuation of treatment …
Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review
N Kerckhove, A Collin, S Condé, C Chaleteix… - Frontiers in …, 2017 - frontiersin.org
Neurotoxic anticancer drugs, such as platinum-based anticancer drugs, taxanes, vinca
alkaloids, and proteasome/angiogenesis inhibitors are responsible for chemotherapy …
alkaloids, and proteasome/angiogenesis inhibitors are responsible for chemotherapy …
Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?
VA Carozzi, A Canta, A Chiorazzi - Neuroscience letters, 2015 - Elsevier
Cisplatin, oxaliplatin, paclitaxel, vincristine and bortezomib are some of the most effective
drugs successfully employed (alone or in combinations) as first-line treatment for common …
drugs successfully employed (alone or in combinations) as first-line treatment for common …
Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature
Commonly used chemotherapeutic agents in oncology/hematology practice, causing toxic
peripheral neuropathy, include taxanes, platinum compounds, vinca alkaloids, proteasome …
peripheral neuropathy, include taxanes, platinum compounds, vinca alkaloids, proteasome …
Platinum-induced neurotoxicity and preventive strategies: past, present, and future
Neurotoxicity is a burdensome side effect of platinum-based chemotherapy that prevents
administration of the full efficacious dosage and often leads to treatment withdrawal …
administration of the full efficacious dosage and often leads to treatment withdrawal …
Platinum‐induced peripheral neurotoxicity: from pathogenesis to treatment
Platinum‐induced peripheral neurotoxicity (PIPN) is a common side effect of platinum‐
based chemotherapy that may cause dose reduction and discontinuation, with oxaliplatin …
based chemotherapy that may cause dose reduction and discontinuation, with oxaliplatin …
A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration
AJM Beijers, F Mols, G Vreugdenhil - Supportive Care in Cancer, 2014 - Springer
Purpose The aim of this study was to systematically review the literature on the influence of
oxaliplatin administration (eg cumulative dose, dose intensity, number of cycles and …
oxaliplatin administration (eg cumulative dose, dose intensity, number of cycles and …
[HTML][HTML] Ion channel expression as promising cancer biomarker
E Lastraioli, J Iorio, A Arcangeli - Biochimica et Biophysica Acta (BBA) …, 2015 - Elsevier
Cancer is a disease with marked heterogeneity in both response to therapy and survival.
Clinical and histopathological characteristics have long determined prognosis and therapy …
Clinical and histopathological characteristics have long determined prognosis and therapy …